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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.014Prolyl hydroxylase domain (PHD) proteins catalyze oxygen-dependent prolyl hydroxylation of hypoxia-
inducible factor 1a and 2a, tagging them for pVHL-dependent polyubiquitination and proteasomal
degradation. In this study, albumin Cre (AlbCre)emediated, hepatocyte-speciﬁc triple disruption of
Phd1, Phd2, and Phd3 (Phd(1/2/3)hKO) promoted liver erythropoietin (EPO) expression 1246-fold,
whereas renal EPO was down-regulated to 6.7% of normal levels. In Phd(1/2/3)hKO mice, hematocrit
levels reached 82.4%, accompanied by severe vascular malformation and steatosis in the liver. In mice
double-deﬁcient for hepatic PHD2 and PHD3 (Phd(2/3)hKO), liver EPO increase and renal EPO loss both
occurred but were much less dramatic than in Phd(1/2/3)hKO mice. Hematocrit levels, vascular or-
ganization, and liver lipid contents all appeared normal in Phd(2/3)hKO mice. In a chronic renal failure
model, Phd(2/3)hKO mice maintained normal hematocrit levels throughout the 8-week time course,
whereas ﬂoxed controls developed severe anemia. Maintenance of normal hematocrit levels in Phd(2/3)
hKO mice was accomplished by sensitized induction of liver EPO expression. Consistent with such a
mechanism, liver HIF-2a accumulated to higher levels in Phd(2/3)hKO mice in response to conditions
causing modest systemic hypoxia. Besides promoting erythropoiesis, EPO is also known to modulate
retinal vascular integrity and neovascularization. In Phd(1/2/3)hKO mice, however, neonatal retinas
remained sensitive to oxygen-induced retinopathy, suggesting that local EPO may be more important
than hepatic and/or renal EPO in mediating protective effects in the retina. (Am J Pathol 2014, 184:
1240e1250; http://dx.doi.org/10.1016/j.ajpath.2013.12.014)Supported by the NIH (grant 5R01-EY019721 to G.H.F.).
Disclosures: None declared.Prolyl hydroxylase domain (PHD) proteins PHD1, PHD2,
and PHD3 usemolecular oxygen as a substrate to hydroxylate
speciﬁc prolyl residues in HIF-1a and HIF-2a,1e3 tagging
them for von HippeleLindau protein (pVHL)edependent
polyubiquitination and proteasomal degradation.4 PHD-
regulated HIF-a stability is important for multiple pro-
cesses, including angiogenesis,5e7 erythropoiesis,8e10
cardiomyocyte function,11e13 cell survival,14 and meta-
bolism.15 PHD1 and PHD2 also hydroxylate IKKb, thus
regulating the assembly of NF-kBand functions ofmonocytic
cells and proangiogenic macrophages.16e19 Besides PHDs, a
transmembrane prolyl hydroxylase in the endoplasmic retic-
ulum (P4H-TM) may also regulate HIF-a stability.20,21
In normal adults, renal interstitial cells are responsible for
the bulk of plasma erythropoietin (EPO) and thus play a key
role in regulating erythropoiesis and blood homeostasis. Lossstigative Pathology.
.or dysfunction of renal interstitial cells due to acute renal
injury or chronic kidney disease can lead to EPO deﬁciency
and severe anemia.22Normal liver expresses EPOonly at very
low levels, but possesses latent capacity for EPO expression
that can be reactivated by manipulations that lead to hepatic
HIF-2a stabilization. For example, hepatocyte-speciﬁc Vhl
knockout in mice resulted in the accumulation of HIF-1a and
HIF-2a to high levels, and subsequent studies showed that
HIF-2a was responsible for elevated liver EPO expression
and polycythemia.23,24 Other studies have also demonstrated
critical roles of HIF-2a in regulating EPO expression.25,26
Our research group has previously shown that germline
Phd1 and Phd3 double knockout leads to increased liver
Phenotypes in Hepatic PHD Knockout MiceEPO expression.8 In a more recent study, Minamishima
and Kaelin27 showed that more dramatic liver EPO up-
regulation can be induced by triple Phd knockout, with
Phd1 and Phd3 knockout being germline null mutations and
Phd2 knockout induced in a hepatocyte-restricted manner.
These studies raised the possibility that the liver may be
exploited as an alternative source for endogenous EPO
production in case of renal failure. Indeed, siRNA-mediated
knockdown of hepatic PHD rescued erythropoiesis in mice
subjected to 5/6 nephrectomy.28 Although these ﬁndings are
highly encouraging, it is not known how the liver itself is
affected by PHD deﬁciency.
In the present study, we examined hematological effects
of hepatic PHD deﬁciency in an established chronic renal
failure model,29e32 and compared blood, vascular, and lipid
phenotypes associated with the disruption of different combi-
nations of PHD isoforms in the liver. Hepatic triple deﬁciency
of all three isoforms caused multiple abnormalities, including
severe erythrocytosis, vascular malformation, and massive
lipid accumulation in the liver. By contrast, mice double-
deﬁcient for hepatic PHD2 and PHD3 did not exhibit any of
these defects, but yet gained the ability to maintain normal
hematocrit (Hct) levels in a chronic renal failure model. These
data provide the proof of principle that selective combinations
of hepatic PHD isoforms could offer suitable therapeutic tar-
gets for maintaining normal blood homeostasis without
accompanying vascular malformation or liver steatosis.
Materials and Methods
Mice
All animal procedures were approved by the Animal Care
Committee at the University of Connecticut Health Center
in compliance with Animal Welfare Assurance. AlbCre mice,
originally generated by the Magnuson Laboratory at Van-
derbilt University,33 were purchased from the Jackson
Laboratory (Bar Harbor, ME). The generation and geno-
typing of ﬂoxed and knockout alleles for Phd1, Phd2, and
Phd3 have been described previously.5,6,8
Chronic Renal Failure Anemia
Chronic renal injury was induced by an adenine-rich diet, as
described previously.29e32 In brief, mice were ﬁrst main-
tained on normal chow until 8 weeks of age, and then were
switched over to an adenine-rich diet (normal chow sup-
plemented with 0.2% adenine) (Harlan Laboratories, Indi-
anapolis, IN) for another 8 weeks. In control groups, mice
were continued on normal chow.
Hemolysis by PHZ
Acute anemia was induced in 8-week-old mice by two intra-
peritoneal injections of phenylhydrazine (PHZ) administered
24 hours apart, at doses of 0 (saline control), 40, 80, orThe American Journal of Pathology - ajp.amjpathol.org120 mg/kg for each injection. At 48 hours after the second
injection, mice were euthanized for blood collection and liver
and kidney tissue isolation.
OIR Model
To examine the effects of oxygen on retinal vascular integ-
rity, neonatal mice were analyzed by the oxygen-induced
retinopathy (OIR) model.34,35 In brief, mice were exposed to
75% oxygen from postnatal day P7 to P12 for phase I, fol-
lowed by another 5 days under ambient air (P12 to P17) for
phase II.
Measurements of Hct, BUN, Hb, and Serum EPO
Blood samples were collected into EDTA-coated micro-
cuvettes (Sarstedt, Newton, NC). Hct and blood hemoglobin
(Hb) values were determined with a scil Vet abc blood
analyzer (Scil Animal Care, Gurnee, IL). The blood analyzer
was periodically calibrated with standards supplied by the
vendor. Additional blood samples were collected into non-
coated tubes for serum preparation, and serum EPO con-
centrations were analyzed with an EPO enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Minne-
apolis, MN) according to the manufacturer’s instructions.
Blood urea nitrogen (BUN) analysis was performed using a
kit from BioAssay Systems (Hayward, CA).
Histology, IHC Staining, and Oil Red O Staining
Mice were perfused under anesthesia with PBS to remove
blood from internal organs, including the liver. Perfused
liver tissues were ﬁxed in 4% paraformaldehyde for 4 hours
at 4C, rinsed with PBS, and dehydrated through ethanol
and toluene. Dehydrated liver tissues were embedded in
parafﬁn, and sections were cut at 5-mm thickness. Vascular
structures were visualized by IHC staining with rat anti-
CD31 (MEC 13.3; BD Biosciences, San Jose, CA) in
conjunction with goat anti-rat IgGehorseradish peroxidase
(Jackson ImmunoResearch Laboratories, West Grove, PA)
and an Elite ABC kit (Vector Laboratories, Burlingame,
CA). To detect liver lipid droplets, cryosections were pre-
pared from ﬁxed liver tissues, and stained with Oil Red O
(Sigma-Aldrich, St. Louis, MO). Vascular lumen size and
percentage areas occupied by vascular structures and lipid
droplets were determined using the Adobe Photoshop CS4
Lasso tool, according to a procedure originally developed
for quantifying neovascular tufts in the mouse OIR model.36
qPCR
Quantitative real-time PCR (qPCR) analyses were per-
formed on an ABI PRISM 7900HT sequence detection
system (Life Technologies, Carlsbad, CA) using SYBR
Green PCR master mix (Life Technologies). The qPCR
primers are listed in Table 1.1241
Table 1 qPCR Primer Sequences
Template Forward Reverse
Phd1 50-CATCAATGGGCGCACCA-30 50-GATTGTCAACATGCCTCACGTAC-30
Phd2 50-TAAACGGCCGAACGAAAGC-30 50-GGGTTATCAACGTGACGGAC-30
Phd3 50-CTATGTCAAGGAGCGGTCCAA-30 50-GTCCACATGGCGAACATAACC-30
VEGF-A 50-CACGACAGAAGGAGAGCAGAAGT-30 50-TTCGCTGGTAGACATCCATGAA-30
SDF1 50-TCCTCTTGCTGTCCAGCTCT-30 50-CAGGCTGACTGGTTTACCG-30
EPO 50-TAGCCTCACTTCACTGCTTCG-30 50-GCTTGCAGAAAGTATCCACTGT-30
FGF1 50-GGACACCGAAGGGCTTTTAT-30 50-GCATGCTTCTTGGAGGTGTAA-30
Ang1 50-CGTCGTGTTCTGGAAGAATGA-30 50-CGTCGTGTTCTGGAAGAATGA-30
Ang2 50-CACACTGACCTTCCCCAACT-30 50-CCCACGTCCATGTCACAGTA-30
FGF2 50-CCAACCGGTACCTTGCTATG-30 50-GATTCCAGTCGTTCAAAGAAGAA-30
MMP9 50-CCTGAAAACCTCCAACCTCA-30 50-GGTGTAACCATAGCGGTACAAGT-30
Duan et alWestern Blotting
Liver nuclear extracts were used for Western blotting. To
prepare nuclear protein extracts, liver tissues were homog-
enized in ice-cold nuclear extraction buffer containing
10 mmol/L HEPES-KOH (pH 7.9), 1.5 mmol/L MgCl2,
10 mmol/L KCl, 0.5 mmol/L dithiothreitol, 0.2 mmol/L
phenylmethylsulfonyl ﬂuoride, 0.2 mmol/L deferoxamine
(Sigma-Aldrich), 0.1% NP-40, and 1 complete protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN).
Nuclei were collected from homogenates by centrifugation.
Pellets were resuspended in ice-cold buffer containing 20
mmol/L HEPES-KOH (pH 7.9), 420 mmol/L NaCl, 1.5
mmol/L MgCl2, 0.5 mmol/L dithiothreitol, 0.2 mmol/L
deferoxamine, 1 protease inhibitor cocktail, 0.2 mmol/L
phenylmethylsulfonyl ﬂuoride, and 25% glycerol. For
Western blotting, the following antibodies were used: antie
HIF-1a (NB100-449; Novus Biologicals, Littleton, CO),
antieHIF-2a (NB100-122 and NB100-132; Novus Bi-
ologicals), and antieb-actin (sc-1616; Santa Cruz Biotech-
nology, Dallas, TX). Band intensities were quantiﬁed using
ImageJ 1.60 software (NIH, Bethesda, MD).
Erythroid EPO Sensitivity Assay
EPO sensitivity of erythroid cells was evaluated by a burst-
forming uniteerythroid (BFU-E) colony formation assay in a
methylcellulose-based semisolid culturemedium (MethoCult
M3234; STEMCELL Technologies, Vancouver, BC, Can-
ada), supplemented with 20 ng/mL IL-3, 50 ng/mL stem cell
factor (SCF) (PeproTech, Rocky Hill, NJ), and recombinant
human EPO (rhEPO) in a range from 0 to 3000 mIU/mL
(eBiosciences, San Diego, CA). Speciﬁcally, bone marrow
cells were isolated from femurs, and plated out at 1 105 cells
per dish (35 mm, low adhesion). BFU-E colonies were scored
at 8 to 10 days after culturing at 37C under 5% CO2.
Labeling, Imaging, and Quantiﬁcation of Retinal Blood
Vessels
Eyes were enucleated from euthanized neonatal mice and
were ﬁxed in 4% paraformaldehyde for 40 minutes at room1242temperature. Retinas were dissected, ﬂat-mounted with four
incomplete radial incisions, and then stained with isolectin B4
conjugated to Alexa Fluor 594 (Life Technologies). Stained
retinas were analyzed by confocal imaging with a Zeiss LSM
510Meta confocal microscope (Carl Zeiss Microscopy, Jena,
Germany). Percentage areas of vascular obliteration and
neovascularization were quantiﬁed using the Adobe Photo-
shop CS4 Lasso tool as described previously.36
Statistical Analysis
Statistical analyses were performed with two-tailed Stu-
dent’s t-test or two-way analysis of variance. Data are
expressed as means  SD or means  SEM. All n values
refer to the number of mice per group. P < 0.05 was
considered signiﬁcant.
Results
Changes in Hct Levels and EPO Expression Due to
Hepatic Triple PHD Deﬁciency
To achieve hepatocyte-speciﬁc Phd disruption, we crossed
mice carrying ﬂoxed Phd1, Phd2, and Phd3 with AlbCre
transgenic mice,33 generating mice with a variety of ﬂoxed
Phd loci and the AlbCre transgene. In Phd1f/f/Phd2f/f/Phd3f/f/
AlbCre (Phd(1/2/3)hKO) mice, Phd1, Phd2, and Phd3 mRNA
levels were reduced by approximately 70%, as estimated by
qPCR of total liver RNA (Supplemental Figure S1A). Given
that the liver also contains other cell types, such as endo-
thelial cells, the speciﬁc percentage losses in hepatocytes
were likely higher. As expected, HIF-1a and HIF-2a protein
levels were increased in liver nuclear extracts from Phd(1/2/
3)hKO mice (Supplemental Figure S1, B and C). qPCR an-
alyses of total liver RNA demonstrated increased expression
of VEGF-A, EPO, angiopoietin 2 (Ang2), and FGF2 species
in Phd(1/2/3)hKO mice (Supplemental Figure S1D).
At 6 weeks of age, Phd(1/2/3)hKO mice had Hct values of
82.4  7.2% (Figure 1A) and substantially increased blood
Hb levels (Figure 1B). Similarly, Phd1f/f/Phd2f/f/Phd3f/þ/
AlbCre (Phd(1/2)f/f/3f/þ/hKO) and Phd1f/þ/Phd2f/f/Phd3f/f/
AlbCre (Phd1f/þ/(2/3)hKO) mice both had signiﬁcantlyajp.amjpathol.org - The American Journal of Pathology
Figure 1 Effects of hepatic PHD deﬁciency on
blood phenotypes and EPO expression. A: Hct
values. B: Blood Hb concentrations. C and D:
Serum EPO levels determined by ELISA. The scale in
D allows resolution of EPO levels too low for the
scale in C (bracket and arrow). E and F: EPO mRNA
abundance, expressed as EPO/b-actin qPCR signal
ratios. Values too low for the main scale (arrow)
are presented at higher resolution in the inset (E).
Data are expressed as means  SD (A and B) or
means  SEM (CeF). n Z 5 to 8 (A and B) or
n Z 6 to 8 (CeF). *P < 0.05, **P < 0.01, and
***P < 0.001, Student’s t-test.
Phenotypes in Hepatic PHD Knockout Miceelevated Hct and Hb values (Figure 1, A and B). Consistent
with these changes, serum EPO concentrations were
increased in mice of all three groups (Figure 1, C and D), but
EPO increases in Phd(1/2/3)hKO mice were by far the most
dramatic, with an average of 135-fold increase over ﬂoxed
controls (Figure 1C).
Increased serum EPO levels were due exclusively to liver
EPO up-regulation. For example, hepatic EPO qPCR signals
were increased 1246-fold in Phd(1/2/3)hKO mice and 338-
fold in Phd1f/þ/(2/3)hKO mice (Figure 1E). Elevated liver
EPO expression was accompanied by reduced EPO
expression in kidney. In Phd(1/2/3)hKO mice, renal EPO
expression was reduced to 6.7% of normal levels, and
expression in Phd(1/2)f/f/3f/þ/hKO and Phd1f/þ/(2/3)hKO
mice was also dramatically reduced (Figure 1F).
In addition to comparisons between PHD-deﬁcient mice
and the respective ﬂoxed mice, we made additional compar-
isons across the various PHD-deﬁcient mice (Supplemental
Figure S2, A and B). The Phd(1/2/3)hKO mice had signiﬁ-
cantly higher serum EPO than either Phd (1/2)f/f/3f/þ/hKO or
Phd1f/þ/(2/3)hKO mice, although differences in Hct levels
were not statistically signiﬁcant. These ﬁndings suggest thatThe American Journal of Pathology - ajp.amjpathol.orgfurther EPO increases beyond those observed in Phd(1/2)f/f/
3f/þ/hKO and Phd1f/þ/(2/3)hKO mice had little effect, pre-
sumably because at such high levels EPO availability is no
longer a limiting factor.
Because polycythemia associated with pVHL deﬁciency
or HIF-2a stabilization induces EPO hypersensitivity in
erythroid cells,37e39 we tested whether erythroid cells in
Phd1f/þ/(2/3)hKO mice are also more sensitive to EPO. In
brief, bone marrow cells were isolated from femurs and
were cultured in semisolid MethoCult medium (STEM-
CELL Technologies) supplemented with appropriate cyto-
kines and different amounts of rhEPO. Our data indicate that
erythroid cells from Phd1f/þ/(2/3)hKO and ﬂoxed mice
responded similarly to stimulation by different concentra-
tions of recombinant EPO (Supplemental Figure S3),
probably because PHD disruption in these mice was limited
to hepatocytes but did not perturb the oxygen-sensing
mechanism in erythroid cells. In experiments in which
EPO hypersensitivity was observed, pVHL deﬁciency or
HIF-2a stabilization was global, and EPO receptor expres-
sion was elevated in erythroid cells because of HIF-2a
stabilization in these cells.1243
Duan et alVascular and Lipid Phenotypes in TripleePHD-Deﬁcient
Livers
Because Vhl knockout led to vascular tumor formation and
fatty liver phenotypes,23 we wondered whether hepatic PHD
deﬁciency might have similar effects. We examined
vascular morphology by anti-CD31 IHC staining of liver
sections (Figure 2, AeH) and quantiﬁed the ﬁndings
(Figure 2, Q and R). Vascular lumen sizes were increased
410% in Phd(1/2/3)hKO mice and 52% in Phd1f/þ/(2/3)
hKO mice, but insigniﬁcantly in Phd(1/2)f/f/3f/þ/hKO mice.
The differences between Phd(1/2/3)hKO and other mice
were signiﬁcant (Supplemental Figure S2C). Percentage
area occupied by vascular structures was increased in all
Phd(1/2/3)hKO, Phd(1/2)f/f/3f/þ/hKO, and Phd1f/þ/(2/3)
hKO mice, relative to their respective ﬂoxed controls. In
contrast to pVHL-deﬁcient mice, vascular tumors were not
found in these PHD-deﬁcient mice.
Oil Red O staining indicated that liver lipid contents were
increased in the aforementioned PHD-deﬁcientmice (Figure 2,
IeP). Quantiﬁcation of percentage area occupied by lipid
droplets showed a relative value of 11:1 between Phd(1/2/3)
hKO and Phd(1/2/3)f/fmice, whereas Phd(1/2)f/f/3f/þ/hKO and
Phd1f/þ/(2/3)hKO mice displayed milder lipid accumulation1244(Supplemental Figure S2). Differential lipid accumulation be-
tween Phd(1/2/3)hKO mice and the other two lines was sta-
tistically signiﬁcant (Supplemental Figure S2D).
Phd(1/2/3)hKO mice generally died by 8 weeks of age.
Although the exact causes are unknown, it is conceivable
that severe liver defects may have contributed to premature
death. Although polycythemia is most likely harmful as
well, it should be noted that both Phd(1/2)f/f/3f/þ/hKO and
Phd1f/þ/(2/3)hKO mice lived over a year, despite high Hct.
Resistance of Phd(1/2)f/f/Phd3 f/þ/hKO and
Phd1f/þ/(2/3)hKO Mice to Renal Failure Anemia
Elevated liver EPO expression due to PHD deﬁciency might
enable these mice to resist renal failure anemia. To address
this possibility, we used a previously established procedure
to induce chronic renal failure by adenine-rich diet.29e32 In
a pilot experiment with wild-type mice, adenine diet led to
rapid and progressive increase in BUN concentrations over
an 8-week period, whereas Hct values gradually decreased
to severely anemic levels (31.3 2.2%, means SEM) (data
not shown). These ﬁndings conﬁrmed that the adenine-diet
model worked similarly in our hands as described in previ-
ous publications.29e31Figure 2 Liver vascular and lipid phenotypes
associated with hepatic PHD deﬁciency. AeH: Anti-
CD31 IHC staining of liver sections from adult mice
differing in genotype (Phd loci) and in AlbCre trans-
gene status. IeP: Oil Red Oestained liver sections.
QeS: Quantiﬁcation of vascular lumen size (Q),
percent area occupied by vascular structures (R), and
percent area occupied by Oil Red Oepositive lipid
droplets (S).Micewere6weeks of agewhenanalyzed.
Data are expressed as means SD. nZ 5 to 8. *P<
0.05, ***P< 0.001, Student’s t-test. Scale barZ 25
mm. Black bars, with AlbCre; white bars, no AlbCre.
ajp.amjpathol.org - The American Journal of Pathology
Phenotypes in Hepatic PHD Knockout MiceWhen Phd(1/2)f/f/3f/þ/hKO and Phd1f/þ/(2/3)hKO mice
were switched to adenine-rich diet for 8 weeks between 8
and 16 weeks of age, BUN concentrations were signiﬁcantly
increased, as in ﬂoxed controls (Supplemental Figure S4, A
and B). However, high Hct levels persisted, whereas all
ﬂoxed controls developed severe anemia (Figure 3, A and
B). Elevated Hct levels in the knockout mice were sup-
ported by several hundred-fold increases in liver EPO
expression, both on normal chow and adenine-rich diet
(Figure 3C). On normal chow, Phd(1/2)f/f/3f/þ/hKO and
Phd1f/þ/(2/3)hKO mice had reduced renal EPO expression,
compared with ﬂoxed controls, whereas the adenine diet
signiﬁcantly reduced renal EPO expression in both Phd(1/
2)f/f/3f/þ and Phd1f/þ/(2/3) mice (Figure 3D).
Normal Hematological and Liver Phenotypes in
Phd(2/3)hKO Mice
In contrast to triple PHD deﬁciency, Phd2f/f/Phd3f/f/AlbCre
(Phd(2/3)hKO) mice had an average Hct level of 53.5 5.4%,
which was not statistically different from the ﬂoxed controls
(Figure 1A). Hb and serum EPO levels also were unaltered
(Figure 1, BeD). Nonetheless, hepatic EPO expression was
increased to 9.1-fold of normal baseline, whereas renal EPO
expression was decreased to 45% of normal values (Figure 1, E
and F). Besides the normal Hct and Hb levels, Phd(2/3)hKO
mice were also apparently normal in liver vascular morphology
and lipid contents (Figure 2, D, H, L, P, and QeS). Life span
was similar for Phd(2/3)hKO and wild-type mice.
On the adenine-rich diet, bothPhd(2/3)f/f andPhd(2/3)hKO
mice displayed increased BUN concentration (Supplemental
Figure S4, C and D), as expected for compromised renal
function. At the end of the 8-week period on the adenine diet,Figure 3 Resistance of Phd1f/þ/(2/3)hKO and Phd(1/2)f/f/3 f/þ/hKOmice to ad
Phd1f/þ/(2/3)hKO (B) mice on normal chow or an adenine-rich diet. Baseline blo
analyses for liver (C) and kidney (D) EPO expression, relative to b-actin. Data are exp
two-way analysis of variance (A and B) or Student’s t-test (C and D). Black bars, a
The American Journal of Pathology - ajp.amjpathol.orgHct levels remained normal in Phd(2/3)hKO mice (48.1 
1.8%), but decreased to 30.5  2.0% in Phd(2/3)f/f mice
(Figure 4A). In both groups of mice, there was no apparent
vascular malformation or liver steatosis after adenine treat-
ment (Supplemental Figure S5). Thus, hepatic PHD2 and
PHD3 double deﬁciency protected mice from adenine-
induced anemia without inﬂicting other abnormalities such
as erythrocytosis, vascular malformation, and liver steatosis.
Serum EPO ELISA did not reveal statistically signiﬁcant
differences between Phd(2/3)hKO and Phd(2/3)f/f mice, nor
between mice on normal chow versus the adenine diet
(Figure 4B).At least in the case ofPhd(2/3)f/fmice, our failure to
detect reduced serum EPO after adenine treatment could have
been due to sensitivity and/or accuracy issues below basal level
concentrations, because adenine-treated Phd(2/3)f/f mice
exhibited all other signs consistent with reduced serum EPO,
including severe anemia, lack of signiﬁcant EPO up-regulation
in the liver, and severely reduced renal EPO mRNA levels.
Because Phd(2/3)hKO mice resisted adenine-induced
anemia, we asked whether hepatic deﬁciency of a single
PHD isoform might confer similar Hct stability. On normal
chow, Phd1f/f/AlbCre, Phd2f/f/AlbCre, and Phd3f/f/AlbCre mice
all had normal Hct levels; when fed with the adenine diet for
8 weeks, all of these mice developed severe anemia
(Supplemental Figure S6). These data indicate that targeting
a single PHD isoform in the liver is not sufﬁcient to resist
renal failure-induced anemia.
Sensitized Liver EPO Induction by Systemic Hypoxia in
Phd(2/3)hKO Mice
Once switched to the adenine diet, Phd(2/3)hKO mice
maintained normal Hct levels by further up-regulating liverenine-induced chronic anemia. A and B: Hct in Phd(1/2)f/f/3f/þ/hKO (A) and
od samples at week 0 were taken just before diet switching. C and D: qPCR
ressed as means SEM. nZ 6. *P< 0.05, **P< 0.01, and ****P< 0.0001,
denine; white bars, chow. ad, adenine diet; chow, normal chow diet.
1245
Figure 4 Maintenance of normal blood homeostasis in Phd(2/3)hKO mice by sensitized liver EPO induction. A: Hct values for Phd(2/3)hKO and Phd(2/3)f/f
mice. All mice were initially maintained on normal chow until 8 weeks of age, after which they were either continued on normal chow or switched to an
adenine-rich diet. Baseline blood samples at week 0 were taken just before diet switching. B: Serum EPO quantiﬁcation by ELISA at 3 weeks and 8 weeks after
diet switching. C: qPCR analysis of liver EPO mRNA levels, normalized to b-actin. D: Representative antieHIF-2a Western blots of liver nuclear extracts from
mice on normal chow or 3 weeks on an adenine diet. The HIF-2a band is detected at approximately 118 kDa. E: Corresponding quantiﬁcation of HIF-2a bands.
F: Kidney EPO mRNA levels, normalized to b-actin. G: Serum EPO levels in 8-week-old mice injected with PHZ at 40 mg/kg. Two doses of PHZ were injected 24
hours apart, and mice were euthanized for analysis at 48 hours after the second injection. H: Representative antieHIF-2a Western blots of liver nuclear
extracts from PHZ- or saline-injected mice. HIF-2a was detected at 118 kDa. I: Corresponding quantiﬁcation of HIF-2a bands. Data are expressed as means 
SEM. nZ 6 (A and B); nZ5 (C and F); nZ 3 (D, E, H, and I). *P < 0.05, **P < 0.01, and ****P < 0.0001, two-way analysis of variance (A) or Student’s t-
test (BeE, G, and H). Black bars, PhD(2/3)hKO; white bars, PhD(2/3)f/f.
Duan et alEPO expression over their already up-regulated levels on
normal chow. Similar increases were not observed in
adenine-treated Phd(2/3)f/f mice (Figure 4C). At the protein
level, adenine-treated Phd(2/3)hKO mice accumulated
higher HIF-2a levels in the liver (Figure 4, D and E),
consistent with sensitized response to systemic hypoxia. In
the kidney, EPO mRNA levels were reduced substantially in
adenine-treated mice, both in Phd(2/3)hKO and Phd(2/3)f/f
groups (Figure 4F). On both normal chow and the adenine
diet, Phd(2/3)hKO mice displayed lower renal EPO
expression levels than Phd(2/3)f/f controls.
To complement the adenine diet experiment, we induced
acute hemolysis by phenylhydrazine (PHZ). At 2 days after
PHZ injection at the 40 mg/kg dose, serum EPO concen-
trations in Phd(2/3)hKO mice were 50.4% higher than in
similarly treated ﬂoxed mice (Figure 4G). In addition,
HIF-2a accumulation selectively occurred in PHZ-treated
Phd(2/3)hKO mice (Figure 4, H and I).
To further investigate sensitivity to systemic hypoxia, we
tested the effects of different PHZ doses. As expected,
higher PHZ doses induced more severe anemia in both
Phd(2/3)hKO and Phd(2/3)f/f mice (Figure 5A). Lack of1246compensatory Hct up-regulation in Phd(2/3)hKO mice can
be explained by the acute nature of the experiment. Serum
EPO concentration increased more substantially with
larger doses of PHZ injection (Figure 5B), apparently as a
feedback response to more severe hemolytic anemia.
Importantly, Phd(2/3)hKO mice had higher serum EPO
levels than ﬂoxed controls at the 40 mg/kg and 80 mg/kg
doses, indicating that these mice were able to respond to
anemia (hypoxia) more sensitively. In support of this pos-
sibility, liver EPO induction in Phd(2/3)hKO mice had more
sensitive dose responses (Figure 5, C and D). In kidney,
PHZ-dependent anemia also triggered EPO up-regulation,
but without noticeable differences between Phd(2/3)hKO
and Phd(2/3)f/f mice (Figure 5, E and F). Overall, these data
suggest that Phd(2/3)hKO mice were sensitized for hepatic
EPO induction in response to systemic hypoxia.
Oxygen-Induced Obliteration of Retinal Microvessels in
Neonatal Mice Triple Deﬁcient for Hepatic PHDs
Retinopathy of prematurity, a leading cause of blindness in
children, is typically associated with oxygen therapy forajp.amjpathol.org - The American Journal of Pathology
Figure 5 PHZ dose response in Phd(2/3)f/f and
Phd(2/3)hKO mice. Two doses of PHZ were injec-
ted 24 hours apart, and mice were euthanized at
48 hours after the second injection. A: Hct values
at 0, 40, 80, and 120 mg/kg/dose. B: Serum EPO
protein levels determined by ELISA. C: Liver EPO
qPCR analysis, normalized to b-actin. Values too
low for the main scale (arrow) are presented at
higher resolution in the inset. D: Dose response of
liver EPO mRNA induction, presented as fold
change of EPO mRNA abundance relative to that in
saline-injected, genotype-matched control mice.
PHD dose response was more sensitive in Phd(2/3)
hKO mice. E: Kidney EPO qPCR signals normalized
against b-actin. F: Dose response of kidney EPO
mRNA induction (fold change relative to baseline
values in saline-injected, genotype-matched con-
trol mice). Data are expressed as means  SEM.
n Z 6 (A and D); n Z 6 to 11 (B, C, E, and F).
*P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001, and *****P < 0.00001, Student’s t-test
(AeC, and E) and two-way analysis of variance (D)
for interaction between PHZ dose and EPO mRNA
abundance. P Z 0.16, two-way analysis of vari-
ance for interaction (F). Black bars, (2/3)hKO;
white bars, (2/3)f/f.
Phenotypes in Hepatic PHD Knockout Micepremature infants. In mice, retinopathy of prematurityelike
phenotypes can be mimicked by OIR. In the OIR model,
neonatal mice are exposed to 75% oxygen for 5 days be-
tween postnatal days P7 and P12 (phase I) followed by
another 5 days (P12 to P17) in ambient room air (phase
II).34,35 In phase I, signiﬁcant microvascular obliteration
occurs. Upon return to ambient air, poor perfusion due to
vascular loss leads to severe hypoxia and neovascularization.
EPO appears to play a protective role in these processes,
because delivery of exogenous EPO to mice protects retinal
microvessels in phase I and reduces neovascularization in
phase II.40 In a related study, systemic delivery of a PHD
inhibitor (dimethyloxalylglycine) to neonatal mice promoted
EPO expression and protected retinal microvessels from
hyperoxia-induced damages.41 Interestingly, there were in-
dications that inhibition of hepatic PHDs might be respon-
sible for the protection of retinal vasculature.
To determine whether triple PHD deﬁciency in the liver
might have similar effects on the retina, we exposed Phd(1/2/
3)hKO and Phd(1/2/3)f/f mice to 75% oxygen from P7 to P12
and analyzed retinal vasculature at P12 immediately after
oxygen treatment or at P17 after 5 days in ambient air. At
P12, Phd(1/2/3)hKO and Phd(1/2/3)f/f mice exhibited similar
levels of microvascular obliteration (Figure 6, AeC). At P17,
robust neovascularization was present to a similar extent in
both groups of mice (Figure 6, DeG). These data indicate
that hepatic deﬁciency of all three PHD isoforms failed to
protect retinas from oxygen-induced vascular injury.The American Journal of Pathology - ajp.amjpathol.orgDiscussion
Differential Blood and Liver Phenotypes among Various
Hepatic PHD-Deﬁcient Mice
Several studies have demonstrated elevated EPO expression
and erythropoiesis in PHD-deﬁcient mice.8,9,27 In particular, a
recent study in an acute renal injury model demonstrated the
feasibility of treating anemia by targeting hepatic PHDs.28
Nonetheless, several important issues remain to be addressed.
First, although the ability to promote EPO expression and
erythropoiesis offers new opportunities for treating anemia, the
associated polycythemia is a health concern. Second, because
hepatic pVHL deﬁciency led to vascular tumors and fatty liver
phenotype,23 it is important to determine whether PHD-
deﬁcient livers develop similar phenotypes. Third, it remains
to be determinedwhether hepatic PHDs are effective targets for
treating anemia in a chronic kidney disease model.
To better understand the roles of liver PHDs, we compared
how hepatic disruption of different combinations of PHD
isoforms might affect blood, vascular, and lipid phenotypes.
Although deﬁciency of all three PHD isoforms in Phd(1/2/3)
hKO mice caused severe erythrocytosis, as well as extensive
vascular malformation and massive accumulation of lipid
droplets in the liver, the presence of a singlewild-typePhd1 or
Phd3 allele inPhd1f/þ/(2/3)hKOorPhd(1/2)f/f/3f/þ/hKOmice
minimized hepatic vascular and lipid abnormalities, although
severe erythrocytosis persisted. In mice double-deﬁcient for1247
Figure 6 Analysis of Phd(1/2/3)hKO mice by OIR model. A and B: Neonatal Phd(1/2/3)hKO mice (B) and their ﬂoxed controls (A) were exposed to 75%
oxygen for 5 days between P7 and P12; the mice were euthanized immediately after oxygen treatment, to examine the extent of vascular obliteration. Retinas
were ﬁxed in 4% paraformaldehyde, ﬂat-mounted with four incomplete radial incisions, and then stained with isolectin B4 conjugated to Alexa Fluor 594.
Confocal images of representative petals are shown. C: Vascular obliteration is shown as percent avascular areas. D and E: Neovascularization in Phd(1/2/3)
hKO mice (E) and their ﬂoxed controls (D) after OIR phase II. Retinas were dissected from P17 mice after 5 days of oxygen exposure (P7 to P12) and another
5 days in ambient air (P12 to P17) and then were stained with isolectin B4eAlexa Fluor 594. Confocal images of representative petals are shown. F and G:
Percent area that remained avascular (F) and percent area occupied by neovascular tufts (G). Data are expressed as means  SEM. nZ 6 (C); nZ 4 (F and G).
Scale bars: 500 mm. Black bars, Phd(1/2/3)hKO; white bars, Phd(1/2/3)f/f. AV, avascular; NV, neovascular tufts.
Duan et alhepatic PHD2 and PHD3, Hct levels remained within a
healthy range on either normal chow or the kidney-damaging
adenine diet, and vascular morphology and lipid deposition
appeared normal in the liver. These observations demonstrate
that liver vascular and lipid defects can be minimized or
avoided by targeting selective combinations of hepatic PHD
isoforms. Meanwhile, we note that our data do not exclude
other isoform combinations as valid targets, such as limited
knockdown of all three PHD isoforms.
EPO Regulation in Mice Deﬁcient for Hepatic PHDs
Phd1f/þ/(2/3)hKO mice exhibited several hundredfold in-
creases in liver EPO mRNA, but only severalfold increases
in serum EPO protein. This apparent paradox can be better
understood by considering at least two issues. First, kidney
EPO expression is dramatically reduced in these mice,
presumably because of feedback inhibition by vastly up-
regulated liver EPO production. Second, because of very
low baseline levels of EPO in normal livers, each fold in-
crease in liver EPO mRNA corresponds to only a small
fraction of the EPO expression capacity in normal kidney.
Based on basal EPO mRNA levels in the liver and kidney,
and at an approximate mass ratio of 4:1 between the liver
and two kidneys, the amount of EPO mRNA in a Phd1f/
þ/(2/3)hKO liver roughly corresponds to the combined
amounts from seven pairs of normal kidneys.
Although these estimates are unlikely to be completely
accurate because of several inherently crude assumptions1248(eg, equal translational efﬁciencies in liver and kidney), they
do help explain why serum EPO is increased by only
severalfold (instead of fold changes in the tens and hun-
dreds) in Phd1f/þ/(2/3)hKO mice. By a similar argument, it
is not surprising that serum EPO in Phd(2/3)hKO mice was
essentially unchanged, despite the approximately ninefold
up-regulation in liver EPO expression. On the adenine diet,
further up-regulated liver EPO expression might have been
offset by compromised renal EPO expression.
Sensitized EPO Induction in PHD2 and PHD3 Double
Deﬁcient Livers
We examined whether PHD2 and PHD3 double-deﬁcient
liver is more sensitive to modest anemia (systemic hypoxia).
After adenine treatment, elevated HIF-2a protein levels
were detected in Phd(2/3)hKO but not Phd(2/3)f/f mice.
Although Phd(2/3)hKO mice were never anemic on either
normal chow or the adenine diet, increased HIF-2a protein
accumulation on the adenine diet suggests that the liver in
these mice was very sensitive to minor downward drifting in
Hct levels and compensated for such changes by HIF-2a
accumulation and hepatic EPO up-regulation, thus pre-
venting further Hct reduction.
We also investigated EPO expression regulation by
inducing hemolytic anemia with PHZ. After PHZ injection,
Phd(2/3)f/f and Phd(2/3)hKO mice developed similar levels
of anemia. The failure of Phd(2/3)hKO mice to maintain
normal Hct levels was apparently due to the acute nature ofajp.amjpathol.org - The American Journal of Pathology
Phenotypes in Hepatic PHD Knockout MicePHZ-induced hemolysis. Liver EPO expression was
increased in both Phd(2/3)f/f and Phd(2/3)hKO mice, but
much more robustly in the latter group. As an indication of
more sensitive response to modest anemia in Phd(2/3)hKO
mice, low-dose PHZ injection promoted liver HIF-2a pro-
tein accumulation more effectively in these mice.
Serum EPO levels were up-regulated with increasing
PHZ doses. Because kidneys remained functional in these
experiments, up-regulated renal EPO expression in response
to anemia may account for most of the blood EPO increases
in PHZ-treated ﬂoxed mice. On the other hand, additional
serum EPO increases in Phd(2/3)hKO mice may be due to
up-regulated liver EPO expression. As expected, the highest
PHZ dose induced the highest serum EPO levels, but the
distinction between Phd(2/3)hKO and ﬂoxed mice was not
obvious at this dose. It is likely that robust renal EPO in-
duction under this condition overshadowed differential liver
EPO expression between Phd(2/3)hKO and Phd(2/3)f/f
mice. Overall, our data indicate that hepatic PHD2 and
PHD3 double deﬁciency indeed confers sensitized response
to systemic hypoxia.
Liver EPO Expression and Oxygen-Induced Retinopathy
Because systemically elevated EPO levels as well as
chemical inhibition of hepatic PHDs had been previously
reported to protect retinal microvessels from oxygen-
induced losses, we also examined Phd(1/2/3)hKO mice by
the OIR model. Retinal microvessels were similarly oblit-
erated by oxygen in Phd(1/2/3)hKO and Phd(1/2/3)f/f mice.
At present, there are no simple explanations for the
discrepancy between our ﬁndings and those in the literature,
but several possibilities exist. For example, retinal vascular
protection by recombinant EPO was found to be dose
dependent.40 It is possible that, at the responsive doses,
recipient mice received even larger amounts of EPO than
was produced in Phd(1/2/3)hKO mice. With regard to PHD
inhibitoremediated protection of retinal blood vessels, he-
patic and retinal EPO expression were both elevated, and the
latter might have made at least some contribution.41 At any
rate, consideration of our genetic data in conjunction with
earlier ﬁndings should facilitate the optimization of EPO-
based therapies for retinal protection.
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